PA
NUTX

PharVision Advisers’s Nutex Health NUTX Stock Holding History

PharVision Advisers’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,133
Closed -$351K – 475
2025
Q4 		$351K Sell
2,133
-1,929
-47% -$256K 0.18% 187
2025
Q3 		$420K Buy
+4,062
New +$398K 0.24% 63

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

PharVision Advisers's NUTX Position: Q1 2026 in Review

PharVision Advisers sold out of Nutex Health (NUTX) in Q1 2026, closing a stake of 2,133 shares — an estimated $351K sold.

PharVision Advisers first reported a position in NUTX in Q3 2025 and held it in 2 quarters. The position peaked at $420K in Q3 2025. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • PharVision Advisers reported no remaining Nutex Health position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 2,133 Nutex Health shares in Q1 2026, an estimated $351K.
  • PharVision Advisers first reported a position in Nutex Health in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Nutex Health position peaked at $420K in Q3 2025.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.